Arcturus Therapeutics (ARCT) Tops Q1 EPS by 6c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($1.00), $0.06 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $30.91 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Oppenheimer Starts Teva Pharma (TEVA) at Outperform
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'